Thomas Schroeder

TL;DR: A phase 2 hypothesis-generating trial to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls.

TL;DR: Findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7–IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans.

TL;DR: Aza and DLI is an effective and well-tolerated treatment option for patients with relapse after allogeneic hematopoietic stem cell transplantation, in particular those with MDS or AML and low disease burden.

TL;DR: A molecular interrelation of neuronal and hematopoietic signaling mechanisms in humans is suggested by cDNA arrays, real-time reverse-transcriptase-polymerase chain reaction (RT-PCR), and fluorescent-activated cell sorter (FACS) analysis focusing on genes involved in neurobiologic functions.

TL;DR: It is proposed that CTA‐specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX‐2.